Oite T, Shimizu F, Batsford S R, Vogt A
Clin Exp Immunol. 1986 May;64(2):318-22.
In vivo studies in rats demonstrated that the binding of a highly cationic antigen (cationized human IgG, pI greater than 9.5) to glomerular polyanion could be significantly reduced by prior application of a small polycation, protamine sulfate. The degree of inhibition was dose dependent and the highest dose used, 4 mg/100 g body weight, reduced antigen binding by approximately 70%. In further experiments the ability of protamine sulfate to enhance elimination of cationic antigen-antibody immune complexes from the glomerular capillary wall was examined. Daily treatment with protamine sulfate, starting after induction of nephritis, produced a significant but only moderate reduction in the persistence of the antigen, without having any effect on proteinuria. Proteinuria could only be prevented when protamine sulfate was given immediately before induction of nephritis. Protamine sulfate had little influence on the course of established renal disease in the model employed. These results do not substantiate the concept of charge competition as a potentially useful therapeutic strategy.
在大鼠体内进行的研究表明，预先应用一种小的聚阳离子硫酸鱼精蛋白，可显著降低一种高度阳离子化抗原（阳离子化人IgG，pI大于9.5）与肾小球多阴离子的结合。抑制程度呈剂量依赖性，所用最高剂量为4mg/100g体重，可使抗原结合减少约70%。在进一步的实验中，研究了硫酸鱼精蛋白增强从肾小球毛细血管壁清除阳离子化抗原-抗体免疫复合物的能力。从肾炎诱导后开始每日用硫酸鱼精蛋白治疗，可使抗原持续存在时间显著但仅适度降低，而对蛋白尿无任何影响。只有在肾炎诱导前立即给予硫酸鱼精蛋白才能预防蛋白尿。在所采用的模型中，硫酸鱼精蛋白对已确立的肾脏疾病进程影响很小。这些结果并未证实电荷竞争作为一种潜在有用治疗策略的概念。
